• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Theratechnologies Inc.

    4/16/25 10:51:02 AM ET
    $THTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $THTX alert in real time by email
    6-K 1 d945933d6k.htm 6-K 6-K
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 6-K

     

     

    REPORT OF FOREIGN PRIVATE ISSUER

    PURSUANT TO RULE 13a-16 OR 15d-16

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    For the month of April 2025.

    Commission File Number 001-35203

     

     

    Theratechnologies Inc.

    (Translation of registrant’s name into English)

     

     

    2015 Peel Street, Suite 1100

    Montreal, Quebec

    H3A 1T8, Canada

    (Address of principal executive office)

     

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

    Form 20-F ☒   Form 40-F ☐

     

     
     


    EXHIBIT INDEX

     

    Exhibit
    No.

      

    Description of Exhibit

    99.1    Press Release Dated April 15, 2025


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

    THERATECHNOLOGIES INC.
    By:   /s/ Jocelyn Lafond

    Name:

     

    Jocelyn Lafond

    Title:

     

    General Counsel and Corporate Secretary

    Date: April 16, 2025

    Get the next $THTX alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $THTX

    DatePrice TargetRatingAnalyst
    11/17/2022$9.00Overweight
    Cantor Fitzgerald
    7/29/2021$8.00 → $3.00Buy → Hold
    Canaccord Genuity
    More analyst ratings

    $THTX
    SEC Filings

    See more
    • SEC Form 6-K filed by Theratechnologies Inc.

      6-K - Theratechnologies Inc. (0001512717) (Filer)

      7/3/25 2:09:15 PM ET
      $THTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Theratechnologies Inc.

      6-K - Theratechnologies Inc. (0001512717) (Filer)

      5/29/25 2:31:33 PM ET
      $THTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Theratechnologies Inc.

      6-K - Theratechnologies Inc. (0001512717) (Filer)

      5/2/25 4:30:17 PM ET
      $THTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $THTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald initiated coverage on Theratechnologies with a new price target

      Cantor Fitzgerald initiated coverage of Theratechnologies with a rating of Overweight and set a new price target of $9.00

      11/17/22 7:27:25 AM ET
      $THTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Theratechnologies downgraded by Canaccord Genuity with a new price target

      Canaccord Genuity downgraded Theratechnologies from Buy to Hold and set a new price target of $3.00 from $8.00 previously

      7/29/21 9:53:58 AM ET
      $THTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Canaccord Genuity reiterated coverage on Theratechnologies with a new price target

      Canaccord Genuity reiterated coverage of Theratechnologies with a rating of Buy and set a new price target of $8.00 from $7.00 previously

      4/19/21 9:31:33 AM ET
      $THTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $THTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Theratechnologies to Announce Second Quarter 2025 Financial Results

      MONTREAL, July 03, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX:TH) (NASDAQ:THTX), a commercial-stage biopharmaceutical company, today announced the Company will report financial results for its second quarter 2025 ended May 31 on Wednesday, July 9, 2025. Given the announcement of July 2, 2025, concerning the acquisition of the Company, a conference call will not be held. About Theratechnologies Theratechnologies (TSX:TH) (NASDAQ:THTX) is a specialty biopharmaceutical company focused on the commercialization of innovative therapies that have the potential to redefine standards of care. Further information about Theratechnologies is availabl

      7/3/25 5:30:00 PM ET
      $THTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Theratechnologies enters into Definitive Agreement to be Acquired by CB Biotechnology, an Affiliate of Future Pak

      Offer of US$3.01 in cash plus one contingent value right for potential additional aggregate payments of up to US$1.19 per shareUpfront and total potential cash consideration represent respectively a 126% and 216% premium to Nasdaq closing price on date prior to announcement of Future Pak's initial non-binding proposalTransaction with Future Pak represents culmination of sale process whereby Theratechnologies solicited interest from a number of potential counterpartiesBoard unanimously recommends that shareholders approve the transaction MONTREAL, July 02, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX:TH) (NASDAQ:THTX), a commercial-stage bio

      7/2/25 10:11:00 PM ET
      $THTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Theratechnologies Reports on its Annual Meeting of Shareholders

      MONTREAL, May 29, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX:TH) (NASDAQ:THTX), a commercial-stage biopharmaceutical company, reported the voting results from its annual meeting of shareholders held today in a virtual-only setting. Shareholders proceeded to elect the below candidates to the Company's Board of Directors for a one-year term, appointed KPMG LLP as the Company's auditors for the current fiscal year and approved the adoption of an omnibus long-term incentive plan for the benefits of the directors, executive officers and employees of the Company and those of its subsidiaries. All candidates proposed for the position of director

      5/29/25 2:00:29 PM ET
      $THTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $THTX
    Leadership Updates

    Live Leadership Updates

    See more
    • Theratechnologies Appoints Elina Tea to its Board of Directors

      MONTREAL, April 05, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX:TH) (NASDAQ:THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the appointment of Elina Tea, Chief Financial Officer at GLS North America, to its Board of Directors and as a member of the Company's Audit Committee. Ms. Tea will be Investissement Québec's designee pursuant to its investor rights agreement with the Company. "Elina Tea's extensive experience in finance, corporate strategy, and investor relations makes her a valuable addition to our Board of Directors," said Dawn Svoronos, Chair of the Board o

      4/5/24 11:00:00 AM ET
      $THTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Theratechnologies Appoints Jordan Zwick to its Board of Directors

      MONTREAL, March 21, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX:TH) (NASDAQ:THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the appointment of Jordan Zwick, Chief Business Officer at Mirador Therapeutics Inc., to its Board of Directors and as a member of the Company's Audit Committee. "We welcome Jordan Zwick to the Board as an important addition to our esteemed group of advisors," said Dawn Svoronos, Chair of the Board of Directors at Theratechnologies. "With his extensive experience in the U.S. biotech and pharmaceutical industry, coupled with expertise in global

      3/21/24 8:00:00 PM ET
      $THTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Theratechnologies Announces the Resignation of One of Its Directors, Mr. Alain Trudeau

      MONTREAL, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX:TH) (NASDAQ:THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that Mr. Alain Trudeau has resigned from the Board of Directors of Theratechnologies and as a member of its Audit Committee, effective immediately. "I want to thank Alain for his contributions to Theratechnologies as a director since joining the Company in October 2020 and for completing the annual review for the 2023 fiscal year", said Dawn Svoronos, Chair of the Board at Theratechnologies. "Alain was the current Chair of the Audit Committee

      2/29/24 4:34:00 PM ET
      $THTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $THTX
    Financials

    Live finance-specific insights

    See more
    • Theratechnologies to Announce Second Quarter 2025 Financial Results

      MONTREAL, July 03, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX:TH) (NASDAQ:THTX), a commercial-stage biopharmaceutical company, today announced the Company will report financial results for its second quarter 2025 ended May 31 on Wednesday, July 9, 2025. Given the announcement of July 2, 2025, concerning the acquisition of the Company, a conference call will not be held. About Theratechnologies Theratechnologies (TSX:TH) (NASDAQ:THTX) is a specialty biopharmaceutical company focused on the commercialization of innovative therapies that have the potential to redefine standards of care. Further information about Theratechnologies is availabl

      7/3/25 5:30:00 PM ET
      $THTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Theratechnologies enters into Definitive Agreement to be Acquired by CB Biotechnology, an Affiliate of Future Pak

      Offer of US$3.01 in cash plus one contingent value right for potential additional aggregate payments of up to US$1.19 per shareUpfront and total potential cash consideration represent respectively a 126% and 216% premium to Nasdaq closing price on date prior to announcement of Future Pak's initial non-binding proposalTransaction with Future Pak represents culmination of sale process whereby Theratechnologies solicited interest from a number of potential counterpartiesBoard unanimously recommends that shareholders approve the transaction MONTREAL, July 02, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX:TH) (NASDAQ:THTX), a commercial-stage bio

      7/2/25 10:11:00 PM ET
      $THTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Theratechnologies Reports Financial Results for the First Quarter 2025 and Reviews Key Achievements

      FDA Approves EGRIFTA WR™ (Tesamorelin F8) to Treat Excess Visceral Abdominal Fat in Adults with HIV and LipodystrophyTotal Revenue $19 million, representing +17% growth year over yearFDA Approves Prior Approval Supplement (PAS) for EGRIFTA SV® sBLALatest from VAMOS study demonstrates excess visceral abdominal fat drives cardiovascular risk MONTREAL, April 09, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX:TH) (NASDAQ:THTX), a commercial-stage biopharmaceutical company, today reported business highlights and financial results for the first quarter 2025, ended February 28, 2025. All figures are in U.S. dollars unless otherwise stated. First-

      4/9/25 7:30:00 AM ET
      $THTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $THTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Theratechnologies Inc.

      SC 13G - Theratechnologies Inc. (0001512717) (Subject)

      2/14/24 4:51:41 PM ET
      $THTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Theratechnologies Inc. (Amendment)

      SC 13G/A - Theratechnologies Inc. (0001512717) (Subject)

      2/7/24 6:55:18 PM ET
      $THTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by Theratechnologies Inc.

      SC 13D - Theratechnologies Inc. (0001512717) (Subject)

      11/28/23 4:52:43 PM ET
      $THTX
      Biotechnology: Pharmaceutical Preparations
      Health Care